Novel oncolytic herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune responses and increased survival in an immunocompetent B16F10-derived mouse melanoma model
Document Type
Article
Publication Date
1-1-2021
Publication Source (Journal or Book title)
Journal of Virology
Recommended Citation
Uche, I., Fowlkes, N., Vu, L., Watanabe, T., Carossino, M., Nabi, R., del Piero, F., Rudd, J., Kousoulas, K., & Ridera, P. (2021). Novel oncolytic herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune responses and increased survival in an immunocompetent B16F10-derived mouse melanoma model. Journal of Virology, 95 (3) https://doi.org/10.1128/JVI.01359-20
COinS